3 16.7% estimated difference between Wegovy (-16.1%) and placebo (+0.6%) at 68 weeks 3 BMI Reduction Thresholds More patients achieved BMI reductions at multiple thresholds with Wegovy injection at week 68 3 Estimated proportion of patients (%) with BMI reduction at week 68 3 Mean baseline BMI: Wegovy =37.7 kg/m 2
Publicerad Foto: Christine Olsson/TT, Henrik Montgomery/TT Ansvarig utgivare: Michael Kucera S verkar du ha stenkoll p VM Nu r VM 2026 slut och Spanien vann
Supports metabolic function
But longer-term studies following patients with Type 2 diabetes found that a significant portion of these patients were also losing weight, and that kind of spurred the interest of using it as a weight-loss drug. The new weight-loss prescriptions fall collectively under the generic identity of semaglutide
These reductions are generally considered moderate sufficient to contribute meaningfully to glycaemic targets, but less potent than agents such as GLP-1 receptor agonists or SGLT-2 inhibitors in head-to-head comparisons
Web of Science Core Collection ESCI (Emerging Sources Citation Index- Clarivate), Google scholar
